Polypharmacy and medication use in patients with chronic kidney disease with and without kidney replacement therapy compared to matched controls

被引:30
|
作者
van Oosten, Manon J. M. [1 ]
Logtenberg, Susan J. J. [2 ]
Hemmelder, Marc H. [3 ,4 ]
Leegte, Martijn J. H. [5 ]
Bilo, Henk J. G. [6 ,7 ,8 ,9 ]
Jager, Kitty J. [1 ]
Stel, Vianda S. [1 ]
机构
[1] Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Dept Med Informat, Amsterdam UMC, Amsterdam, Netherlands
[2] Diakonessen Hosp, Dept Internal Med, Utrecht, Netherlands
[3] Maastricht Univ, Dept Internal Med, Div Nephrol, Med Ctr, Maastricht, Netherlands
[4] Maastricht Univ, Cardiovasc Res Inst Maastricht, Maastricht, Netherlands
[5] Nefrovisie Fdn, Dutch Renal Registry, Utrecht, Netherlands
[6] Isala Hosp, Diabet Res Ctr, Zwolle, Netherlands
[7] Isala Hosp, Dept Epidemiol & Stat, Zwolle, Netherlands
[8] Univ Med Ctr Groningen, Dept Internal Med, Groningen, Netherlands
[9] Univ Groningen, Fac Med, Groningen, Netherlands
关键词
CKD; dialysis; health claims data; kidney transplantation; medication use; polypharmacy; AMBULATORY HEMODIALYSIS-PATIENTS; PILL BURDEN; OLDER-ADULTS; EPIDEMIOLOGY; MANAGEMENT; COST;
D O I
10.1093/ckj/sfab120
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. This study aims to examine polypharmacy (PP) prevalence in patients with chronic kidney disease (CKD) Stage G4/G5 and patients with kidney replacement therapy (KRT) compared with matched controls from the general population. Furthermore, we examine risk factors for PP and describe the most commonly dispensed medications. Methods. Dutch health claims data were used to identify three patient groups: CKD Stage G4/G5, dialysis and kidney transplant patients. Each patient was matched to two controls based on age, sex and socio-economic status (SES) score. We differentiated between 'all medication use' and 'chronic medication use'. PP was defined at three levels: use of >= 5 medications (PP), >= 10 medications [excessive PP (EPP)] and >= 15 medications [hyper PP (HPP)]. Results. The PP prevalence for all medication use was 87, 93 and 95% in CKD Stage G4/G5, dialysis and kidney transplant patients, respectively. For chronic medication use, this was 66, 70 and 75%, respectively. PP and comorbidity prevalence were higher in patients than in controls. EPP was 42 times more common in young CKD Stage G4/G5 patients (ages 20-44years) than in controls, while this ratio was 3.8 in patients >= 75years. Older age (64-75 and >= 75years) was a risk factor for PP in CKD Stage G4/G5 and kidney transplant patients. Dialysis patients >= 75years of age had a lower risk of PP compared with their younger counterparts. Additional risk factors in all patients were low SES, diabetes mellitus, vascular disease, hospitalization and an emergency room visit. The most commonly dispensed medications were proton pump inhibitors (PPIs) and statins. [GRAPHICS] . Conclusions. CKD Stage G4/G5 patients and patients on KRT have a high medication burden, far beyond that of individuals from the general population, as a result of their kidney disease and a large burden of comorbidities. A critical approach to medication prescription in general, and of specific medications like PPIs and statins (in the dialysis population), could be a first step towards more appropriate medication use.
引用
收藏
页码:2497 / 2523
页数:27
相关论文
共 50 条
  • [41] Association between Polypharmacy and the Risk of Chronic Kidney Disease in the Elderly Patients
    Won, Heehyun
    Lim, Eunsun
    Jeong, Na-Young
    Choi, Nam-Kyong
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 566 - 566
  • [42] Aminoglycosides use has a risk of acute kidney injury in patients without prior chronic kidney disease
    Chu-Lin Chou
    Nai-Chen Chuang
    Hui-Wen Chiu
    Chia-Te Liao
    Yung-Ho Hsu
    Tzu-Hao Chang
    Scientific Reports, 12
  • [43] Aminoglycosides use has a risk of acute kidney injury in patients without prior chronic kidney disease
    Chou, Chu-Lin
    Chuang, Nai-Chen
    Chiu, Hui-Wen
    Liao, Chia-Te
    Hsu, Yung-Ho
    Chang, Tzu-Hao
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [44] Use of vasopressors in patients with acute kidney injury on continuous kidney replacement therapy
    Ramesh, Ambika
    Doddi, Akshith
    Abbasi, Aisha
    Al-Mamun, Mohammad A.
    Sakhuja, Ankit
    Shawwa, Khaled
    PLOS ONE, 2024, 19 (12):
  • [45] Total arch replacement in patients with chronic kidney disease
    Hachiro, Kohei
    Kinoshita, Takeshi
    Suzuki, Tomoaki
    Asai, Tohru
    JOURNAL OF CARDIAC SURGERY, 2021, 36 (02) : 475 - 482
  • [46] Inappropriateness of medication prescriptions about chronic kidney disease patients without dialysis therapy in a Chinese tertiary teaching hospital
    Yang, Ping
    Chen, Na
    Wang, Rong-Rong
    Li, Lu
    Jiang, Sai-Ping
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1517 - 1524
  • [47] Risks for mortality and renal replacement therapy in atherosclerotic renovascular disease compared with other causes of chronic kidney disease
    Ritchie, James
    Green, Darren
    Alderson, Helen V.
    Chiu, Diana
    Sinha, Smeeta
    Kalra, Philip A.
    NEPHROLOGY, 2015, 20 (10) : 688 - 696
  • [48] Clinical pharmacists' scope of knowledge for medication therapy management in chronic kidney disease patients
    Shivaprasad, Sirimalla
    Mateti, Uday Venkat
    Shenoy, Pradeep
    Shastry, Chakrakodi Shashidhara
    Dharmagadda, Sreedhar
    PHARMACY EDUCATION, 2021, 21 (01): : 781 - 788
  • [49] Frequency of Fabry disease in chronic kidney disease patients including patients on renal replacement therapy in Korea
    Cho, Eunjung
    Park, Jung Tak
    Yoo, Tae-Hyun
    Kim, Soo Wan
    Park, Cheol Whee
    Han, Seung Seok
    Kim, Yeong Hoon
    Kwon, Young Joo
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2024, 43 (01) : 71 - 81
  • [50] PSYCHOSOCIAL FACTORS (DEPRESSION, ANXIETY AND SOCIAL ISOLATION) AND THEIR INFLUENCE ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE AND USE OF KIDNEY REPLACEMENT THERAPY
    Mckercher, C.
    Venn, A.
    Blizzard, C. L.
    Nelson, M.
    Palmer, A. J.
    Ashby, M.
    Scott, J.
    Jose, M.
    NEPHROLOGY, 2012, 17 : 52 - 52